Back to search
FDAFDA · Food and drugs·Recall number D-0217-2025

Carvedilol 25 mg Tablet, QTY: 30 Tablets per Blister Pack (3 x 10 blister cards), Rx Only, MFG by: Glenmark, Mahwah, NJ 07430, Repackaged by: RemedyRepack Inc., Indiana, PA 15701, NDC: 70518-3945-00.

Published February 12, 2025 · Recall initiated: January 24, 2025

Summary

FDA records drug Class II recall D-0217-2025, published February 12, 2025 and initiated January 24, 2025. Recalling firm: RemedyRepack Inc.; Status: Terminated; Reported quantity: 247 blister packs; Lot: Lot #s: J0777493050824, Exp. 5/31/2025; J0787856062124, Exp. 7/31/2025. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

CGMP deviations: presence of N-Nitroso Carvedilol Impurity-1 (NNC 1), above the FDA recommended acceptable intake limit.

What to do

Voluntary: Firm initiated · Letter

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
RemedyRepack Inc.
Distributor
FL
Lot
Lot #s: J0777493050824, Exp. 5/31/2025; J0787856062124, Exp. 7/31/2025.
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Carvedilol 25 mg Tablet, QTY: 30 Tablets per Blister Pack (3 x 10 blister cards), Rx Only, MFG by: Glenmark, Mahwah, NJ 07430, Repackaged by: RemedyRepack Inc., Indiana, PA 15701, NDC: 70518-3945-00. recalled?

Yes. FDA published recall D-0217-2025 on February 12, 2025. Reported hazard: CGMP deviations: presence of N-Nitroso Carvedilol Impurity-1 (NNC 1), above the FDA recommended acceptable intake limit.

What should I do if I have this product?

Voluntary: Firm initiated · Letter